Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. RESULTS: Among 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. CONCLUSIONS: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with BRAFV600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAFV600E tumors as single agents [93] or in combination with chemotherapy [94].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [94]
In the citing paper
“Additional rare mutations of KRAS, as well as mutations of NRAS, have been associated with primary resistance to treatment.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [35]
In the citing paper
“Further analysis of molecular subgroups in this study showed that adding panitumumab significantly improved mPFS and mOS in the non-mutated KRAS group but was ineffective in patients with KRAS non-exon 2 mutations [15].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [15]
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
In the citing paper
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16,17,18].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 5×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
InfluentialSelf-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 4×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
InfluentialSelf-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 3×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Self-citation
Research works printed but not linked: 2
- Wojcik P, 2008, Pol J Pathol, 59, 93
- Yuen ST, 2002, Cancer Res, 62, 6451
Cited by
Items 201–300 of 1,008
Huyghe, N. D., Baldin, P., & den Eynde, M. V. (2019) · Gastroenterology report · doi:10.1093/gastro/goz061 · Cited by 117
Li, Z.-N., Zhao, L., Yu, L.-F., & Wei, M.-J. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa022 · Cited by 104
“Patients with mCRC with mutations in NRAS exons 2, 3, and 4 showed a poor overall response rate (ORR) and an adverse effect on progression-free survival (PFS) and OS [18, 21, 22].”
BackgroundPrognostic and predictive response factors in colorectal cancer patients: Between hope and reality
Divitiis, C. D., Nasti, G., Montano, M., Fisichella, R., Iaffaioli, R. V., & Berretta, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15049 · Cited by 130
García-Foncillas, J., Alba, E., Aranda, E., Díaz-Rubio, E., López-López, R., Tabernero, J., & Vivancos, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx501 · Cited by 101
Self-citationCurrent and future biomarkers in colorectal cancer
Zarkavelis, G., Boussios, S., Papadaki, A., Katsanos, K. H., Christodoulou, D. K., & Pentheroudakis, G. (2017) · Annals of Gastroenterology · doi:10.20524/aog.2017.0191 · Cited by 120
Gagnière, J., Dupré, A., Gholami, S., Pezet, D., Boerner, T., Gönen, M., Kingham, T. P., Allen, P. J., Balachandran, V. P., DeMatteo, R. P., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002968 · Cited by 107
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells
Mangiapane, L. R., Nicotra, A., Turdo, A., Gaggianesi, M., Bianca, P., Franco, S. D., Sardina, D. S., Veschi, V., Signore, M., Beyes, S., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323553 · Cited by 110
“18 In addition to acquired genetic mutations, the activation of a positive human epidermal growth factor receptor 2 (HER2) and HER3 feed-back loop seems to be one example of antitumour therapy escape.”
EPMA position paper in cancer: current overview and future perspectives
Grech, G., Zhan, X., Yoo, B. C., Bubnov, R. V., Hagan, S., Danesi, R., Vittadini, G., & Desiderio, D. M. (2015) · The EPMA Journal · doi:10.1186/s13167-015-0030-6 · Cited by 109
“Recently, because mutations of RAS have been established as predictive factors for anti-EGFR monoclonal antibody treatment, the treatment has also been more effective in patients with all RAS wild-type tumors rather than just those with a RAS mutation [177].”
BackgroundSystemic treatment of pancreatic cancer revisited
Ducreux, M., Seufferlein, T., Van Laethem, J.-L., Laurent-Puig, P., Smolenschi, C., Malka, D., Boige, V., Hollebecque, A., & Conroy, T. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.12.003 · Cited by 99
Khattak, M. A., Martin, H. L., Davidson, A., & Phillips, M. R. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.011 · Cited by 116
Su, J., Zhang, E., Han, L., Yin, D., Liu, Z., He, X., Zhang, Y., Feng, L., Lin, Q., Mao, P., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.83 · Cited by 99
Guo, F., Gong, H. F., Zhao, H., Chen, J., Zhang, Y., Zhang, L., Shi, X., Zhang, A., Jin, H., Zhang, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24306-1 · Cited by 102
c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival
Lee, S. J., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Park, Y. S., & Kim, S. T. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.013 · Cited by 100
Siena, S., Sartore-Bianchi, A., Garcia-Carbonero, R., Karthaus, M., Smith, D., Tabernero, J., Van Cutsem, E., Guan, X., Boedigheimer, M., Ang, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx504 · Cited by 97
“KRAS and NRAS, exons 2, 3, and 4) are well-established biomarkers for lack of response in patients with metastatic colorectal cancer (mCRC) receiving anti-epidermal growth factor receptor (EGFR) antibody therapy [1].”
BackgroundSelf-citationSukhai, M. A., Craddock, K. J., Thomas, M., Hansen, A. R., Zhang, T., Siu, L., Bedard, P., Stockley, T. L., & Kamel-Reid, S. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.47 · Cited by 97
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Ziemke, E. K., Dosch, J. S., Maust, J. D., Shettigar, A., Sen, A., Welling, T. H., Hardiman, K. M., & Sebolt-Leopold, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0829 · Cited by 97
“With an incidence rate that is considerably lower (1%–4%) than those in exon 2, these mutations as well as those of NRAS are also negative predictive biomarkers for anti-EGFR therapy (4, 25).”
Lee, M. S., McGuffey, E. J., Morris, J. S., Manyam, G., Baladandayuthapani, V., Wei, W., Morris, V. K., Overman, M. J., Maru, D. M., Jiang, Z.-Q., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.87 · Cited by 98
A practical guide to biomarkers for the evaluation of colorectal cancer
Chen, W., & Frankel, W. L. (2018) · Modern Pathology · doi:10.1038/s41379-018-0136-1 · Cited by 108
Objective response rate assessment in oncology: Current situation and future expectations
Aykan, N. F., & Özatlı, T. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i2.53 · Cited by 106
Role of targeted therapy in metastatic colorectal cancer
Ohhara, Y., Fukuda, N., Takeuchi, S., Honma, R., Shimizu, Y., Kinoshita, I., & Dosaka-Akita, H. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.642 · Cited by 96
Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis
Brandi, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.519 · Cited by 96
Malapelle, U., Vigliar, E., Sgariglia, R., Bellevicine, C., Colarossi, L., Vitale, D., Pallante, P., & Troncone, G. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202691 · Cited by 102
Thierry, A. R., Pastor, B., Jiang, Z.-Q., Katsiampoura, A. D., Parseghian, C., Loree, J. M., Overman, M. J., Sanchez, C., Messaoudi, S. E., Ychou, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0232 · Cited by 97
“Further reports have confirmed this technique and highlight the potential of cfDNA as a powerful way to longitudinally follow cancer patients (27, 28).”
Pellino, G., Gallo, G., Pallante, P., Capasso, R., Stefano, A. D., Maretto, I., Malapelle, U., Qiu, S., Nikolaou, S., Barina, A., et al. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/2397863 · Cited by 105
“Among the 656 patients with KRAS-WT exon 2, 108 (17%) had other mutations in KRAS exon 3 or 4, in NRAS exons 2, 3, or 4, or in BRAF exon 15 [217].”
BackgroundGuo, T., Wu, Y., Tan, C., Jin, Y., Sheng, W., Cai, S., Liu, F., & Xu, Y. (2019) · International Journal of Cancer · doi:10.1002/ijc.32489 · Cited by 104
“A few studies have reported a poor prognosis associated with NRAS mutations.(8,40,41) However, very few studies reported the prognostic value of NRAS mutations at specific stages.”
BackgroundAssociation between KRAS mutation and lung metastasis in advanced colorectal cancer
Pereira, A. A. L., Rego, J. F. M., Morris, V, Overman, M. J., Eng, C., Garrett, C. R., Boutin, A. T., Ferrarotto, R., Lee, M., Jiang, Z.-Q., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.619 · Cited by 94
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
Goldstein, D. A., Ahmad, S. B., Chen, Q., Ayer, T., Howard, D. H., Lipscomb, J., El‐Rayes, B. F., & Flowers, C. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.9569 · Cited by 101
“Moreover, there are meaningful data to support the addition of either cetuximab (chimeric immunoglobulin G1 isotype antibody) or panitumumab (human immunoglobulin G1 isotype antibody) to chemotherapy in patients with RAS wild-type disease.(23-32) These biologic agents, however, are not without significant cost, and th…”
BackgroundCiardiello, F., Normanno, N., Martinelli, E., Troiani, T., Pisconti, S., Cardone, C., Nappi, A., Bordonaro, R., Rachiglio, A. M., Lambiase, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw136 · Cited by 100
Sorolla, A., Wang, E., Golden, E., Duffy, C., Henriques, S. T., Redfern, A. D., & Blancafort, P. (2019) · Oncogene · doi:10.1038/s41388-019-1056-3 · Cited by 104
“subsequent clinical development in humans [52].”
Impact of somatic mutations on patterns of metastasis in colorectal cancer.
Lipsyc, M. D., & Yaeger, R. D. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.045 · Cited by 94
“J Gastrointest Oncol 2015;6(6):645-649 www.”
BackgroundInfluentialBRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Hall, R. D., & Kudchadkar, R. R. (2014) · Cancer Control · doi:10.1177/107327481402100307 · Cited by 93
Unveiling the role of KRAS in tumor immune microenvironment
Xu, M., Zhao, X., Wen, T., & Qu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116058 · Cited by 102
BRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
Ciombor, K. K., Strickler, J. H., Bekaii-Saab, T. S., & Yaeger, R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02541 · Cited by 92
Lacouture, M. E., Anadkat, M. J., Jatoi, A., Garawin, T., Bohac, C., & Mitchell, E. P. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.12.004 · Cited by 110
New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer
Sánchez-Gundín, J., Fernández-Carballido, A. M., Valdivieso, L. M., Barreda-Hernández, D., & Torres‐Suárez, A. I. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.24453 · Cited by 101
“However, patients with mutations in exon 2 of KRAS are predictive of good outcomes for panitumumab treatment [25].”
BackgroundKou, T., Kanai, M., Yamamoto, Y., Kamada, M., Nakatsui, M., Sakuma, T., Mochizuki, H., Hiroshima, A., Sugiyama, A., Nakamura, E., et al. (2017) · Cancer Science · doi:10.1111/cas.13265 · Cited by 93
Kidess, E., Liu, H. E., Triboulet, M. M., Che, J., Ramani, V. C., Visser, B. C., Poultsides, G. A., Longacre, T. A., Marziali, A., Vysotskaia, V. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13350 · Cited by 98
“KRAS and BRAF mutation status are predictive for whether a patient may respond to treatment with EGFRinhibitors, such as cetuximab [7-10].”
BackgroundMethodStanley, A., Ashrafi, G. H., Seddon, A. M., & Modjtahedi, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-04301-8 · Cited by 99
Mauri, G., Pizzutilo, E. G., Amatu, A., Bencardino, K., Palmeri, L., Bonazzina, E. F., Tosi, F., Carlo Stella, G., Burrafato, G., Scaglione, F., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.006 · Cited by 90
Self-citationZaidi, S. H. E., Harrison, T. A., Phipps, A. I., Steinfelder, R. S., Trinh, Q. M., Qu, C., Banbury, B. L., Georgeson, P., Grasso, C. S., Giannakis, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17386-z · Cited by 95
Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer
Huang, A., Yang, Y., Shi, J.-Y., Li, Y., Xu, J., Cheng, Y. Q., & Gu, J. (2021) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v13.i12.1567 · Cited by 104
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Napolitano, S., Martini, G., Ciardiello, D., Tufo, S. D., Martinelli, E., Troiani, T., & Ciardiello, F. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00479-x · Cited by 108
Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations
Cercek, A., Braghiroli, M. I., Chou, J. F., Hechtman, J. F., Kemeny, N., Saltz, L., Capanu, M., & Yaeger, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0400 · Cited by 86
“The clinical implications of NRAS mutation beyond lack of response to anti-EGFR therapy (4) and whether these tumors behave similarly to KRAS-mutant mCRC are not known.”
BackgroundLiquid biopsy for cancer: review and implications for the radiologist
Underwood, J. J., Quadri, R. S., Kalva, S. P., Shah, H., Sanjeeviah, A. R., Beg, M. S., & Sutphin, P. D. (2020) · Radiology · doi:10.1148/radiol.2019182584 · Cited by 87
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
“NRAS is a proto-oncogene from the RAS family and its mutations on exon 2, 3, and 4 have been shown to be effective predictors of anti-EGFR resistance [Douillard et al. 2013; Heinemann et al. 2014].”
BackgroundLeto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
“The relatively high cumulative frequency of rare KRASmutations and NRAS mutations, coupled with initial successful validation in prospective trials, strongly advocates prompt incorporation of such biomarkers into clinical practice as negative predictors [35].”
Giordano, G., Febbraro, A., Tomaselli, E., Sarnicola, M. L., Parcesepe, P., Parente, D., Forte, N. R., Fabozzi, A., Remo, A., Bonetti, A. V., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0225-7 · Cited by 96
“Cancer is driven by activating mutations and aberrant signal transduction node, most of which (RAS, PTEN, EGFR) play a significant role in the prediction of resistance to epidermal growth factor receptor (EGFR) monoclonal antibodies in mCRC treatment, whereas, equivalent reliable predictors of bevacizumab are currentl…”
Carrato, A., Abad, A., Massutí, B., Grávalos, C., Escudero, P., Longo-Muñoz, F., Manzano, J.-L., Gómez, A., Safont, M. J., Gallego-Plazas, J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.024 · Cited by 87
Self-citationModest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., Fischer von Weikersthal, L., Caca, K., Kretzschmar, A., Goekkurt, E., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01332 · Cited by 86
“INTRODUCTION Previously untreated patients with microsatellite-stable metastatic colorectal cancer (mCRC) are typically treated with combinations of fluorouracil and folinic acid (FU/FA) plus either oxaliplatin (FOLFOX) or irinotecan or with all three agents.(1-8) Additionally, monoclonal antibodies targeting either t…”
BackgroundYoshino, T., Cervantes, A. M. R., Bando, H., Martinelli, E., Oki, E., Xu, R., Mulansari, N. A., Babu, K. G., Lee, M. A., Tan, C., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101558 · Cited by 105
Mattia, E. D., Cecchin, E., & Toffoli, G. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.003 · Cited by 97
Ali, S. M., Pal, S. K., Wang, K., Palma, N. A., Sanford, E. M., Bailey, M., He, J., Elvin, J. A., Chmielecki, J., Squillace, R. M., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0241 · Cited by 94
Strategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
“Indeed, around 40% of CRC harbors KRAS mutations plus an additional 4% NRAS mutations (and a negligible <1% prevalence of HRAS mutations), with >95% of them occurring in KRAS G12, G13, or Q61 codons.(4,11,12) G12”
BackgroundSelf-citationPietrantonio, F., Cremolini, C., Petrelli, F., Bartolomeo, M. D., Loupakis, F., Maggi, C., Antoniotti, C., de Braud, F., Falcone, A., & Iacovelli, R. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.016 · Cited by 99
Blank, A., ROBERTS, D. E., Dawson, H., Zlobec, I., & Lugli, A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00234 · Cited by 106
Precision medicine in colorectal cancer: the molecular profile alters treatment strategies
Tran, N. H., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Clipson, L., Matkowskyj, K. A., & Deming, D. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015591952 · Cited by 84
New trends in molecular and cellular biomarker discovery for colorectal cancer
Aghagolzadeh, P., & Radpour, R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i25.5678 · Cited by 95
Bronte, G., Silvestris, N., Castiglia, M., Galvano, A., Passiglia, F., Sortino, G., Cicero, G., Rolfo, C., Peeters, M., Bazan, V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4959 · Cited by 84
Cushman, S. M., Jiang, C., Hatch, A. J., Shterev, I. D., Sibley, A. B., Niedzwiecki, D., Venook, A. P., Owzar, K., Hurwitz, H. I., & Nixon, A. B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2313 · Cited by 91
“Recent studies have identified mutations in exon 3 and 4 of KRAS and exons 2, 3, and 4 of NRAS as additional markers of resistance to anti-EGFR antibodies in colorectal cancer (9, 10).”
Liu, J. F., Ray-Coquard, I. L., Selle, F., Poveda, A. M., Cibula, D., Hirte, H. W., Hilpert, F., Raspagliesi, F., Gladieff, L., Harter, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1891 · Cited by 88
Self-citationXie, J., Xia, L., Xiang, W., He, W., Yin, H., Wang, F., Gao, T., Qi, W., Yang, Z., Yang, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918845117 · Cited by 81
“To date, ∼30 to 50% of CRC patients are diagnosed with somatic KRAS mutation in exon 2, which is an established predictive biomarker of resistance to anti-EGFR drugs (4, 5).”
Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications
Minoli, M., Kiener, M., Thalmann, G. N., Julio, M. K., & Seiler, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165670 · Cited by 92
“In the case of EGFR, it was shown in colon cancer that RAS mutations (KRAS and HRAS) can inhibit the response to EGFR-targeted therapy [91,156].”
BackgroundParseghian, C. M., Sun, R., Woods, M. N., Napolitano, S., Lee, H. M., Alshenaifi, J. Y., Willis, J. A., Nunez, S., Raghav, K. P. S., Morris, V. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01423 · Cited by 91
Yamada, T., Iwai, T., Takahashi, G., Kan, H., Koizumi, M., Matsuda, A., Shinji, S., Yamagishi, A., Yokoyama, Y., Tatsuguchi, A., et al. (2016) · Cancer Science · doi:10.1111/cas.12959 · Cited by 85
Lupo, B., Sassi, F., Pinnelli, M., Galimi, F., Zanella, E. R., Vurchio, V., Migliardi, G., Gagliardi, P. A., Puliafito, A., Manganaro, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8313 · Cited by 83
“Consistent with observations in patients (15), all these responsive cases were wild type for clinically validated resistance mutations (KRAS, NRAS, and BRAF) (Fig.”
BackgroundMethodInfluentialFilip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 98
Multisciplinary management of patients with liver metastasis from colorectal cancer
Greef, K. E. D., Rolfo, C. D., Russo, A., Chapelle, T., Bronte, G., Passiglia, F., Coelho, A., Papadimitriou, K., & Peeters, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7215 · Cited by 98
Shitara, K., Yamanaka, T., Denda, T., Tsuji, Y., Shinozaki, K., Komatsu, Y., Kobayashi, Y., Furuse, J., Okuda, H., Asayama, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy526 · Cited by 89
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16–18].”
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82
Self-citationColorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
Li, W., Qiu, T., Zhi, W., Shi, S., Zou, S., Ling, Y., Shan, L., Ying, J., & Lu, N. (2015) · BMC Cancer · doi:10.1186/s12885-015-1345-3 · Cited by 79
“Finally, we did not examine other less common mutations in KRAS codons 61, 117 and 146, which are also the negative predictive marker for response to anti-EGFR therapy [54].”
BackgroundMicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer
Stiegelbauer, V., Perakis, S., Deutsch, A., Ling, H., Gerger, A., & Pichler, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i33.11727 · Cited by 83
Ram, T., Singh, A. K., Kumar, A., Singh, H., Pathak, P., Grishina, M., Khalilullah, H., Jaremko, M., Emwas, A.-H. M., Verma, A., et al. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00145h · Cited by 88
RAS and BRAF in metastatic colorectal cancer management
Gong, J., Cho, M., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.12 · Cited by 78
“com findings have been observed across several phase III trials (22,32,33,36,37,41,42,59).”
BackgroundXue, P., Zeng, F., Duan, Q., Xiao, J., Liu, L., Yuan, P., Fan, L., Sun, H., Malyarenko, O. S., Lü, H., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.001 · Cited by 87
“About 40% of CRC patientswithwild type EGFR, KRAS, or BRAF are still resistant to anti-EGFR treatment (Bardelli and Siena, 2010; De Roock et al., 2010; Douillard et al., 2013).”
BackgroundEnabling Precision Oncology Through Precision Diagnostics
Brown, N. A., & Elenitoba‐Johnson, K. S. J. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012735 · Cited by 93
“In colorectal cancer,KRAS andNRASmutations are associated with primary resistance to anti-EGFR antibody therapy (46, 47).”
BackgroundOncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
García‐Foncillas, J., Tabernero, J. M., Élez, E., Aranda, E., Benavides, M., Camps, C., Lewintre, E. J., López‐López, R., Muinelo‐Romay, L., Montagut, C. O., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0293-5 · Cited by 89
Self-citationSystemic treatment for metastatic colorectal cancer in the era of precision medicine
Sandhu, J. S., Lavingia, V. K., & Fakih, M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25421 · Cited by 86
“The combination of FOLFOX with or without anti‐EGFR therapy was evaluated in two randomized phase III clinical trials.(50,52) The PRIME T A B L E 5 K ey p h as e II I fi rs t‐ lin e an ti ‐E G F R St u d ie s in m et as ta ti c co lo re ct al ca n ce r (r es u lt s fo r R A S‐ W T p o p u la ti o n gr o u p )”
MethodRossini, D., Antoniotti, C., Lonardi, S., Pietrantonio, F., Moretto, R., Antonuzzo, L., Boccaccino, A., Morano, F., Brugia, M., Pozzo, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00839 · Cited by 90
Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer
Fang, L., Yang, Z., Zhou, J., Tung, J.-Y., Hsiao, C., Wang, L., Deng, Y., Wang, P., Wang, J., & Lee, M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0030 · Cited by 86
Activation of the PERK-ATF4 pathway promotes chemo-resistance in colon cancer cells
Shi, Z., Yu, X., Yuan, M., Lv, W., Feng, T., Bai, R., & Zhong, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39547-x · Cited by 80
Veluchamy, J. P., Spanholtz, J., Tordoir, M., Thijssen, V. L., Heideman, D. A. M., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157830 · Cited by 82
Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures
Schumacher, D., Andrieux, G., Boehnke, K., Keil, M., Silvestri, A., Silvestrov, M., Keilholz, U., Haybaeck, J., Erdmann, G., Sachse, C., et al. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008076 · Cited by 80
ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development
Fang, L., Lu, W., Choi, H. H., Yeung, S.-C. J., Tung, J.-Y., Hsiao, C.-D., Fuentes-Mattei, E., Menter, D., Chen, C., Wang, L., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.004 · Cited by 80
“For example, RAS and BRAF mutations have impact on the clinical management of CRC (Amado et al., 2008; Bardelli and Siena, 2010; Douillard et al., 2013; Pietrantonio et al., 2015).”
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Consistent with BRAF V600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAF V600E tumors as single agents [93] or in combination with chemotherapy [94].”
BackgroundMahasneh, A., Al-Shaheri, F., & Jamal, E. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.05.005 · Cited by 79
“Also, indicates that using antiEGFR regimen is not feasible (Douillard et al., 2013, Heinemann and Stintzing, 2014) 3.2.”
MethodInfluentialState of the art in anti-cancer mAbs
Chiavenna, S. M., Jaworski, J. P., & Vendrell, A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-016-0311-y · Cited by 82
“Importantly, the use of this mAb was associated with a detrimental effect in mutated patients [23].”
BackgroundXu, J.-M., Wang, Y., Wang, Y.-L., Wang, Y., Liu, T., Ni, M., Li, M.-S., Lin, L., Ge, F.-J., Gong, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2738 · Cited by 76
“Cetuximab is currently recommended for patients with mCRC expressing wild-type RAS (1).”
BackgroundMethodDienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77
“, wild-type KRAS and NRAS) population (4).”
BackgroundSelf-citationClinical Trials and Progress in Metastatic Colon Cancer
Mody, K., & Bekaii‐Saab, T. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.11.008 · Cited by 80
Mauri, G., Gori, V., Bonazzina, E. F., Amatu, A., Tosi, F., Bencardino, K. B., Ruggieri, L., Patelli, G., Arena, S., Bardelli, A., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102112 · Cited by 87
Self-citationDouillard, J.-Y., Siena, S., Peeters, M., Koukakis, R., Terwey, J.-H., & Tabernero, J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.026 · Cited by 67
Self-citationThe Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taieb, J., Jung, A., Sartore-Bianchi, A., Peeters, M., Seligmann, J., Zaanan, A., Burdon, P., Montagut, C., & Laurent-Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 76
Exploring the best treatment options for BRAF-mutant metastatic colon cancer
Taieb, J., Lapeyre-Prost, A., Laurent Puig, P., & Zaanan, A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0526-2 · Cited by 74
Texture analysis imaging “what a clinical radiologist needs to know”
Corrias, G., Micheletti, G., Barberini, L., Suri, J. S., & Saba, L. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.110055 · Cited by 82
Huiskens, J., van Gulik, T. M., van Lienden, K. P., Engelbrecht, M. R. W., Meijer, G. A., van Grieken, N. C. T., Schriek, J., Keijser, A., Mol, L., Molenaar, I. Q., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1323-9 · Cited by 82
“and NRAS exon 2 and 3) mutations were confirmed [22,23].”
BackgroundCserepes, M., Ostoros, G., Lohinai, Z., Raso, E., Barbai, T., Timar, J., Rozsas, A., Moldvay, J., Kovalszky, I., Fabian, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.001 · Cited by 73
“Recent studies in colorectal cancer found prognostic [22] and both chemotherapy- and anti-EGFR treatment-related predictive effects of subtype-specific codon 12 and 13KRASmutations [23–25].”
BackgroundTherapeutic strategy in unresectable metastatic colorectal cancer: an updated review
Chibaudel, B., Tournigand, C., Bonnetain, F., Richa, H., Benetkiewicz, M., André, T., & de Gramont, A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015572343 · Cited by 82
Guren, T. K., Thomsen, M., Kure, E. H., Sorbye, H., Glimelius, B., Pfeiffer, P., Österlund, P., Sigurdsson, F., Lothe, I. M. B., Dalsgaard, A. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.93 · Cited by 74
“Extended RAS analyses have demonstrated lack of response to EGFR antibodies also in patients with tumours harbouring other KRAS (exons 3 and 4) or NRAS mutations (Douillard et al, 2013; Bokemeyer et al, 2015; Van Cutsem et al, 2015).”
Influential
Metadata
- Authors
- Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., & Patterson, S. D.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-12
- Volume
- 369
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085633477
- Cited by
- 2,263
- References
- 31
- Citations by year
- 2026: 67 · 2025: 98 · 2024: 110 · 2023: 113 · 2022: 125 · 2021: 203 · 2020: 159 · 2019: 178 · 2018: 181 · 2017: 228 · 2016: 251 · 2015: 290 · 2014: 239 · 2013: 16
- FWCI
- 142.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, FOLFOX4, metastatic colorectal cancer, RAS mutations, KRAS exon 2, NRAS, BRAF mutation, anti-EGFR therapy, predictive biomarkers, progression-free survival, overall survival, oxaliplatin, 5-fluorouracil, leucovorin, treatment efficacy and safety, prognostic factors, combination chemotherapy
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.